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Background: Botulinum neurotoxin A (BoNT-A) is a highly neurotoxic drug and frequently used in patients.
Knowledge on the optimal way of administration of BoNT-A and its subsequent distribution is still rather limited. An
accurate method for monitoring these processes might be the use of radiolabelled BoNT-A. In this paper, we report
our feasibility study on labelling BoNT-A with high-dose iodine-125 (125I) via IODOGEN-coated BoNT-A method.
Methods: Using cetuximab as model substrate for BoNT-A, a miniaturization of the IODOGEN-coated mAb method
was developed with special attention to the minimum required amount of the oxidant IODOGEN, while the amount
of substrate, reaction volume and reaction time were downsized. Labelling efficiency and radiochemical purity were
determined by TLC, integrity by SDS-PAGE and HPLC and immunoreactivity by cell-binding assay. BoNT-A (50 μg)
was labelled with 125I by coating with 2.5 μg IODOGEN, in a total reaction volume of 250 μL and a reaction time of
90 s. 125I-BoNT-A was purified by size exclusion chromatography (PD10 column) using ascorbic acid solution
(5 mg/ml, pH = 5) as eluent. Quality analysis of 125I-BoNT-A was performed by an in vitro bladder strip model, an
electrochemiluminescence assay and an Endopep assay.
Results: Cetuximab (50 μg) labelling with 125I (15 to 150 MBq) resulted in a labelling efficiency of 70% to 80%, a
radiochemical purity of >99%, an immunoreactivity of >95% and a retained integrity on SDS; HPLC analysis revealed
partly affected integrity when 110 to 150 MBq 125I was used, i.e. when the averaged I/mAb molar ratio exceeded 3.
Addition of HEPES (20 mM) and lactose (1.25%) (lyophilized BoNT-A contains HEPES and lactose) decreased the
labelling efficiency to 44% to 54%. BoNT-A (50 μg) labelling with 125I (97.2 to 98.3 MBq) resulted in labelling
efficiency of 51% to 52% with a radiochemical purity >98.5%, a specific activity of 150.5 to 152.9 MBq/nmol and an
I/BoNT-A molar ratio of 1.86 to 1.90. The in vitro bladder strip model showed no bioactivity of 125I-BoNT-A when
compared to unlabelled BoNT-A. The electrochemiluminescence and Endopep assay demonstrated around 10%
and 15% bioactivity of 125I-BoNT-A compared to unlabelled BoNT-A, respectively. The remaining bioactivity
correlates within the Poisson distribution with the amount of BoNT-A molecules that does not bear an iodine atom.
Conclusions: BoNT-A was successfully radio-iodinated with an activity high enough to enable in vivo measurement
of nanograms of BoNT-A, which could be used in studying optimization of administration techniques of BoNT-A.
The bioactivity of a BoNT-A molecule is, however, lost upon the introduction of an iodine atom into the tyrosine
moiety of this sensitive molecule.
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Botulinum neurotoxin A (BoNT-A) was introduced for
the treatment of overactive bladder (OAB) by Schurch
et al. at the beginning of this century [1]. Since then,
multiple clinical trials have proven BoNT-A to be an
effective therapy for refractory OAB [2]. These clinical
trials also demonstrated differences in efficacy and du-
ration of the response. The most effective dose, volume
of dilution, number and sites of injection required for
effective treatment are not well known [3]. Notwith-
standing evolving knowledge about the mechanism of
action of BoNT-A on neurotransmitter release and re-
ceptor activation, the distribution of BoNT-A after intra-
vesical injection remains largely unknown [4,5]. If the
distribution in the bladder wall after administration of
BoNT-A could be monitored, the differences in clinical
effect among patients might be better understood. Be-
sides, monitoring would enable investigation of the most
optimal technique of administrating BoNT-A.
An accurate monitoring approach would be to label
the 150 kD BoNT-A molecule (Figure 1) with a long
living PET radioisotope like 124I or 89Zr, albeit with great
demands on the conditions for the radiochemical reac-
tion. Only nanograms of BoNT-A can be used in in vivo
studies, due to its extremely high neurotoxicity (LD50 in
humans is 1 ng/kg [6]). This implies that in order toFigure 1 BoNT-A molecule with heavy chain, light chain and
disulphide connection. The heavy chain (100 kD) is important for
docking and endocytosis of BoNT-A in the nerve end terminal. In
the nerve end terminal, the light chain (50 kD) cleaves SNAP-25
protein, which is essential in the fusion of acetylcholine vesicles with
the nerve end membrane [17].enable detection with a PET camera, nanogram amounts
of BoNT-A must be labelled with a high amount of
radioactivity (high specific activity). Given a patient blad-
der injection dose of 2 ng, we calculated that 1 ng
should contain at least 1 kBq, which corresponds with a
specific activity of at least 150 MBq/nmol. To achieve
this goal, a non-oxidative labelling route making use of
an ester is rather problematic, since with tiny amounts
of substrate hydrolysis of the ester is the main reaction
at pH 9 to 9.5. Besides this, BoNT-A is nowadays sup-
plied as lyophilized powder containing HEPES, so to
reach pH 9 to 9.5, one has to break through the buffe-
ring capacity of HEPES in a controlled way as additional
complicating factor. Therefore, the most straightforward
route to arrive at 150 MBq/nmol seemed to be elec-
trophilic radio-iodination, taking 125I as the research
isotope for the 124I-PET isotope. Radio-iodination of
BoNT-A has been reported earlier, but with the Bolton
Hunter method, in accordance with what was stated
above, only a specific activity of 8.1 MBq/nmol was ob-
tained [7], while miscellaneous remaining bioactivity was
obtained with chloramine-T [8].
The so-called IODOGEN-coated mAb method [9], ori-
ginally developed for high-dose radio-iodination in a
large reaction volume, has been shown to give results
superior to the chloramine-T method and IODOGEN-
coated vial method [9,10]. In this paper we report the
development of a new radio-iodination method for
obtaining optimal quality substrates in the 50-μg range,
using cetuximab as model substrate. Next, our results
with this miniaturized form of the IODOGEN-coated
mAb method on the high-dose labelling of BoNT-A and
its quality control are described.
Methods
Materials
The mAb cetuximab (Erbitux; 5 mg/mL) was purchased
from Merck (Darmstadt, Germany) and was buffer ex-
changed on a PD10 column (GE Healthcare Life Sciences,
Eindhoven, The Netherlands) to a solution of 0.9% NaCl
before radiolabelling. 125I (12.95 GBq/mL in 0.1 M NaOH,
pH 12 to 14, no-carrier added, specific activity 643.8 GBq/
mg) was purchased from Perkin Elmer (Groningen, The
Netherlands). 1,3,4,6-tetrachloro-3α, 6α-diphenyl-glycouril
(IODOGEN, MW 432.1) was supplied by Pierce (Oud
Beijerland, The Netherlands). Pure BoNT-A (vials of
100 μg, 150 kD) from Clostridium botulinum, lyophilized
powder containing 20 mM HEPES and 1.25% lactose when
reconstituted with 100 μL buffer, was supplied by Sigma-
Aldrich (Zwijndrecht, The Netherlands). The reference
BoNT-A was obtained from Metabiologics (Madison, WI,
USA). The human squamous cell carcinoma cell line A431
was obtained from the American Type Culture Collection
(ATCC number CRL-15555).
Table 1 Technical protocol 125I labelling of BoNT-A
according to IODOGEN-coated method
Step
1. X μL 125I is added to wobbling reaction vial
2. 250 μL phosphate buffer (0.5 M, pH 7.4) is added
3. 50 μL BoNT-A/ phosphate buffer (=50 μg BoNT-A) is addeda
4. 115-X μL phosphate buffer (0.1 M, pH 6.8) is added to adjust
the reaction volume to 215 μL
5. 17.5 μL freshly prepared IODOGEN/acetonitrile solution
(2.5 μg/35 μL) is added into the reaction mixture (start of
reaction, t = 0)
6. At t = 45 s, another 17.5 μL IODOGEN/acetonitrile solution
(2.5 μg/35 μL) is added
7. At t = 90 s, 100 μL ascorbic acid solution (25 mg/mL, pH 5.0)
is added to stop the reaction and to reduce any formed
S-Cl bonds
8. At t = 4.30 min, 10 μL BSA (50 mg/mL) is addedb
9. At t = 5.30 min, samples are taken for ITLC for determination
of the labelling efficiency
10. At t = 10 min, 360 μL reaction mixture is transferred to a
syringe connected to a filterc
11. The reaction vial is rinsed by 640 μL phosphate buffer
(0.1M, pH 6.8) and also transferred to the syringe connected
to the filterc
12. The combined solution in the syringe is filtered and purified
on a PD10 column with ascorbic acid solution (5 mg/mL,
pH 5.0) as eluent, collected fractions were 0.5 mL
13. Fractions with highest amount of 125I-BoNT-A and the highest
radiochemical purity are pooled
14. Samples of the pooled 125I-BoNT-A (fractions 6, 7, 8) are taken
for ITLC
15. Final product is diluted by BSA (1 mg/mL) till a concentration
of 1 μg/100 μL and stored at 20°C
t = time.
aVial of 100 μg lyophilized BoNT-A powder is reconstituted with 100 μL
phosphate buffer (0.1 M, pH 6.8).
bFor encapsulation of the product to protect against radiation damage and to
prevent absorption of material on the surface of the vials/syringes. Instead of
BSA (bovine serum albumin), HSA (human serum albumin) or any other
macromolecule can be used.
cFilter of 0.2 μm (Acrodisc Gelman Sciences, Ann Arbor, MI, USA).
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To avoid working routinely with 50 μg portions of ex-
tremely neurotoxic and expensive BoNT-A (LD50 in
humans is about 75 ng [6]), developing and establishing
the optimal method of labelling BoNT-A with 125I was
done with cetuximab.
The coating approach was evaluated by several sets of
labelling experiments within the following general frame:
1) every reaction was performed in a sterilized glass vial
of 20 mL, which was wobbling continuously during the
reaction; 2) the total reaction volume was 250 μL and
consecutively consisted of X μL 125I in 0.1 M NaOH,
50 μL 0.5 M phosphate buffer (pH 7.4), 25 μL mAb solu-
tion (50 μg mAb, 2 mg/mL), 140-X μL 0.1 M phosphate
buffer (pH 6.8) and 35 μL of IODOGEN/acetonitrile so-
lution (1 mg/mL stock IODOGEN/acetonitrile solution
was diluted to the desired amount of IODOGEN); 3) the
reaction was started by IODOGEN/acetonitrile solution
and abrogated with 100 μL ascorbic acid (25 mg/mL, pH
5); 4) labelling yields of all experiments were assessed
with instant thin-layer chromatography (ITLC).
In the first set, labelling efficiency was determined upon
decreasing the amount of IODOGEN (35, 20, 10, 5 and
2.5 μg), using 15 MBq 125I (75 MBq 125I/100 μL) and a re-
action time of 180 s. In the second set, labelling kinetics
was evaluated for 2.5 μg IODOGEN and a reaction time
of 60, 90 and 180 s. In the third set, the amount of radio-
activity of 125I was increased from 15 to 150 MBq. After
PD10 column purification, the integrity was evaluated by
high-performance liquid chromatography (HPLC) and
sodium dodecylsulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) and the immunoreactivity by a cell-binding
assay. In the fourth set, 50 μL HEPES (20 mM) and
12.5 μL lactose solution (50 mg/mL) was included in the
reaction mixture of the cetuximab labelling. The influence
of HEPES and lactose was studied, because lyophilized
BoNT-A also contained these amounts of HEPES and lac-
tose. The total dose of IODOGEN was either 2.5 μg in
one portion, or it was added in two portions; 1.25 μg/17.5
μL IODOGEN/acetonitrile at the start of the reaction and
a second portion after 45 s. Ten microlitres of bovine
serum albumin (BSA pH 6.8; 50 mg/mL) was added to the
reaction mixture before the PD10 column purification.
Again, integrity was analysed by HPLC and SDS-PAGE. In
the fifth set, 50 μg BoNT-A (50 μL) was labelled with 97.2
to 98.3 MBq 125I (10 μL) using the protocol described in
Table 1. Special procedures were applied due to high
neurotoxicity of BoNT-A, including the use of a biological
safety cabinet, double rubber gloves, double-containment
and contamination-free pipettes (Microman, Gilson,
France). CAUTION: during try-outs with cetuximab, it
was found that the advised safety measures (hypochlorite
containing waste bin, spraying of vessels that came out of
the biological safety cabinet with hypochlorite solution)completely destroyed the immunoreactivity of this mAb;
So, these safety measures had to be left out. Geometry and
calibration experiments were performed with 125I-labelled
cetuximab to correct for self-absorption of the 125I-
gamma’s in the various double containment vessels. Reco-
very of the 125I-BoNT-A mass was calculated as 50 μg
times [MBq 125I in product] / [MBq 125I in starting vial
times the labelling efficiency factor]. 125I-BoNT-A and un-
labelled BoNT-A were diluted in BSA/phosphate buffer
(1 mg/mL) to a concentration of 1 μg/100 μL, and these
batches were stored at −20°C.
Quality analysis of mAb labelling
Conjugates were analysed by ITLC for labelling effi-
ciency and radiochemical purity, by HPLC and SDS-
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and by a cell-binding assay for immunoreactivity. ITLC
analysis of radiolabelled cetuximab was performed on
silica gel-impregnated glass fibre sheets (PI Medical
Diagnostic Equipment BV, Tijnje, The Netherlands), with
citrate buffer (20 mM, pH 5.0) as the mobile phase.
HPLC of the conjugates was performed on a JASCO
Benelux BV HPLC (De Meern, The Netherlands) with a
diode array detector system and an inline radiodetector
(Raytest Isotopenmessgeräte GmbH, Straubenhardt,
Germany) using a Superdex 200 10/300 GL size exclu-
sion column (GE Healthcare Life Sciences, Eindhoven,
The Netherlands). The eluent consisted of 0.05 M so-
dium phosphate/0.15 M sodium chloride plus 0.05%
sodium azide (pH 6.8), and the flow was set at a rate of
0.5 mL/min. HPLC measurements were performed at
A = 280 nm to measure mAb absorption. Gel elec-
trophoresis was performed on a Pharmacia Phastgel
System using 7.5% SDS-PAGE gel electrophoresis gels
(Amersham Biosciences, Roosendaal, The Netherlands)
under non-reducing conditions and analyzed on a phos-
phor imager (Molecular Dynamics, Zoetermeer, The
Netherlands) and quantified with ImageQuant software.
In vitro binding characteristics of radiolabelled cetu-
ximab were determined in an immunoreactivity assay es-
sentially as described before [11], using A431 cells fixed
with 2% paraformaldehyde. Binding data were graphic-
ally analysed in a modified Lineweaver-Burk (double-
reciprocal) plot, and the immunoreactive fraction was
determined by linear extrapolation to conditions repre-
senting infinite antigen excess.
Quality analysis of BoNT-A labelling
The bioactivity of 125I-BoNT-A was measured by an
in vitro bladder strip model, an electrochemilumines-
cence (ECL) assay to measure the antibody-antigen de-
tection on the heavy chain and an Endopep assay to
measure the cleavage activity of the light chain.
The animal experiments were performed according to
the Dutch National Institutes of Health principles of la-
boratory animal care and Dutch national (‘Wet op de
dierproeven,’ Stb 1985, 336). The bladders of female
Wistar rats (n = 2, 250 to 300 g, Harlan®, Horst, The
Netherlands) were used for the in vitro bladder strip
experiments previously described [12]. In short: two
bladder strips of one rat bladder were mounted in two
parallel organ baths. One strip was incubated in 125I-
BoNT-A (0.3 mM) and one in unlabelled BoNT-A (0.3
mM). The contraction force of bladder strips due to
electric field stimulation (EFS) was measured before and
after incubation. The second quality analysis of 125I-
BoNT-A was by ECL assay [13]. The ECL assay is based
on antibody docking of the heavy chain of BoNT-A,
which is in this case the antigen. ECL 96-well plateswere coated with BoNT-A capture antibodies. The un-
labelled BoNT-A, reference BoNT-A (TNO, Rijswijk, The
Netherlands) and 125I-BoNT-A were diluted in concentra-
tions of 20, 5, 1.25, 0.31, 0.078, 0.02 and 0.005 ng/mL.
These various concentrations were pipetted in the wells,
and the plate was stirred and washed. The wells were filled
with MSD-labelled detection antibody, stirred and washed.
Finally, the wells were filled with READ buffer and the sig-
nals could be read with the ECL instrument (PR-100,
Meso Scale Discovery, Gaithersburg, MD, USA).
The third quality analysis of 125I-BoNT-A was by
Endopep assay [14]. This assay is based on the cleavage
activity of the light chain. Unlabelled BoNT-A, reference
BoNT-A and 125I-BoNT-A were diluted in concentrations
of 0.5, 0.2, 0.1, and 0.02 ng/μL. These samples were mixed
with 20 μL Endopep reaction buffer (20 mM HEPES pH
7.3, 200 μM ZnCl2, 1 mg/mL BSA and 10 mM DTT). Sub-
strate peptide (KGSNRTRIDQGNQRATR-NLeu-LGGK);
10 μL, 100 μM) was added, and the mixture was incubated
at 36°C overnight. The activity of the light chain of BoNT-
A was measured in a capillary electrophoresis instrument
with laser-induced fluorescence (LIF) detection (Beckman
Instruments, Fullerton, CA, USA). The excitation wave-
length was 488 nm, and the emission wavelength was
520 nm. The total length of the fused silica capillary (i.e.
75 μm, PolyMicro, Phoenix, AZ, USA) was 67 cm; effec-
tive length to the detector was 60 cm. The separation volt-
age was 15 kV. Samples were introduced by pressure
injection for 5 s at 0.5 psi. The running buffer consisted of
60 mM sodium hydroxide and 18 mM phosphoric acid,
pH 12.
Results
Radiolabelling of mAb and BoNT-A
Labelling of 50 μg cetuximab with 15 MBq 125I using
IODOGEN-coated mAb method in 250 μL reaction vol-
ume and reaction time of 90 s resulted in a labelling
yield of 70% to 80%. There was no difference in labelling
yield by using 35 μg till 2.5 μg IODO-GEN. Also, no
substantial increase in labelling yield was observed for a
reaction time above 90 s. The same conditions and an
increase of amount of radioactivity to 150 MBq resulted
in a labelling yield of 71% to 81% (Table 2). ITLC
showed that the radiochemical purity of the products
was ≥99% after size exclusion chromatography (PD10).
The phosphor imager analysis of the SDS-PAGE gel of
the 73.1 MBq, 112.2 MBq and 150.0 MBq reactions is
depicted in Figure 2. It revealed unaffected integrity with
respect to molecular weight: only the presence of the
major 150 kD BoNT-A band and a low amount (0.1% to
0.4%) of free iodine was observed. The HPLC analysis
resulted in an unaffected integrity up to the 73.1 MBq
reaction and a partly impaired integrity increasing for
the 112.2 MBq and 150.0 MBq reactions (shown for 73.1
Table 2 Results of iodination of cetuximab with increasing amount of 125I
Cetuximab (μg) 125I (MBq) Labelling efficiency (%) Radiochemical purity (%) Immunoreactivity (%) 125I/mAb molar ratioa
50 15.0 71.4 99.1 95.2 0.40
50 48.4 75.2 99.7 ND 1.36
50 73.1 81.9 99.3 96.9 2.29
50 112.2 72.9 99.8 ND 3.05
50 150.0 77.0 99.4 96.8 4.30
Conditions: 2.5 μg IODOGEN, 250 μL reaction volume and 90-s reaction time. ND = not determined.
a100 MBq 125I corresponds with 1.24 nmol I atoms.
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lar weight was unaffected (Figure 2) and any formed S-
Cl bonds are reduced by ascorbic acid, this remarkable
finding indicates that a too heavy load of iodine atoms
induces a conformational change of the mAb molecule.
It was, therefore, decided that BoNT-A should not be la-
belled with an I/BoNT-A molar ratio higher than two,
even though the immunoreactivity of 125I-cetuximab did
not change by increasing the amount of radioactivity
(Table 2). To determine the influence of HEPES and lac-
tose on the labelling reaction, both were added to the re-
action mixture. Lactose had no effect on the labelling
yield, but addition of HEPES induced a decrease inFigure 2 Phosphor imager picture of SDS-PAGE gel of the product
from the 125I-cetuximab labelling reaction. The 125I-cetuximab
labelling reaction with 73.1, 112.2 and 150.0 MBq with miniaturized
IODOGEN-coated mAb method demonstrating unaffected integrity
with respect to the molecular weight. Conditions: 50 μg (0.33 nmol)
cetuximab, 2.5 μg (5.7 nmol) IODOGEN, 250 μL reaction volume, 90-s
reaction time.labelling yield from 80.7% to 43.5% (Table 3). The
addition of IODOGEN/acetonitrile reagent in two por-
tions increased the labelling efficiency from 43.5% to
51.8%. The radiochemical purity was >98.5%. As before,
the product with 125I/mAb molar ratio of 2.3 showed
immunoreactivity of ≥95% and unaffected integrity of
the product.
BoNT-A (50 μg) labelling with 125I (97.2 to 98.3 MBq)
by the developed method resulted in a labelling effi-
ciency of 51.5% to 51.8% and a radiochemical purity
of 98.9% (Table 3). The specific activity was 150.5 to
152.9 MBq/nmol BoNT-A. Unlike unlabelled BoNT-A
(0.3 mM), 125I-BoNT-A (0.3 mM) did not result in in-
hibition of bladder strip contraction induced by elec-
trical field stimulation (Figure 4). The ECL signal from
125I-BoNT-A was about 10% of the signal of unlabelled
BoNT-A and of the reference-BoNT-A (Figure 5A). The
Endopep signal from 125I-BoNT-A was about 15% of
the Endopep signal of unlabelled BoNT-A and of the
reference-BoNT-A (Figure 5B).
Discussion
In this article, a novel method is described for high-dose
125I labelling of macromolecules on microgram scale.
A special feature of this miniaturized form of the
IODOGEN-coated mAb method is the low amount (5.7
nmol) of the oxidizing agent IODOGEN required to ar-
rive at efficient labelling yields. For cetuximab labelling,
yields of 70% to 80% were obtained; in the presence of
HEPES and lactose, the yields were 43% to 52%. Conju-
gates with high specific activity and with full retention of
immunoreactivity and integrity were produced, provided
the averaged I/mAb molar ratio was kept below 3. The
labelling of BoNT-A to a level of specific activity ne-
cessary for sensitive detection by PET, i.e. 1 kBq/ng
BoNT-A, was accomplished by this IODOGEN-coated
BoNT-A method in a yield of 51% to 53%. The bioac-
tivity of 125I-BoNT-A, however, was found to be ser-
iously impaired when compared to unlabelled BoNT-A
in three different assays. In an in vitro rat bladder strip
model, contraction inhibition was not observed in case of
125I-BoNT-A. A reason could be a lower total amount of
125I-BoNT-A or a change of bioactivity of 125I-BoNT-A.
Figure 3 HPLC chromatograms of 125I-cetuximab after PD10 column purification. Channel A shows the UV absorption of cetuximab at 280
nm at a retention time of 26 min (large peak at 42 min is from ascorbic acid). Channels B and C represent the radioactive signal of 125I-cetuximab
from the 73.1 MBq and 150.0 MBq reaction demonstrating retained and impaired integrity, respectively.
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batch of dry powder BoNT-A (100 μg) was dissolved in
100 μL phosphate buffer, in a weighing controlled way.
Again controlled by weighing, 50 μL of this solution was
used for a labelling reaction whereas the remaining 50 μL
was diluted to a concentration of 1 μg/100 μL unlabelled
BoNT-A and compared with a reference sample of
BoNT-A (TNO) by determining the heavy and light
chain bioactivity by antibody-antigen detection with
ECL - and Endopep assay. Both assays gave for the un-
labelled BoNT-A similar results as the reference BoNT-A,
indicating that no dissolution mishap had occurred and
that the amount of BoNT-A at the start of the labelling re-
action was indeed the anticipated 50 μg. At the same time,Table 3 Results of iodination of cetuximab with addition of H
Product (50 μg) HEPES (μmol) Lactose (mg) IODOGEN (μg)
Cetuximab 0 0 2.5
Cetuximab 0 0.625 2.5
Cetuximab 1 0 2.5
Cetuximab 1 0.625 2.5
Cetuximab 1 0.625 1.25 + 1.25
Cetuximab 1 0.625 1.25 + 1.25
Cetuximab 1 0.625 1.25 + 1.25
BoNT-A -a -a 1.25 + 1.25
BoNT-A -a -a 1.25 + 1.25
Conditions: 2.5 μg IODOGEN in 35 μL IODOGEN/acetonitrile added at t = 0 or 1.25 μ
conditions: 250 μL reaction volume and 90-s reaction time. Radiochemical purity wa
aReconstituted BoNT-A contained HEPES (20 mM) and lactose (1.25%); this was notthe results of the ECL assay and the Endopep assay there-
fore implied 125I-BoNT-A had lost a great deal of its
bioactivity.
In the 50 μg BoNT-A situation, the IODOGEN/BoNT-A
molar ratio was 17; and under these conditions, no detect-
able harm to cetuximab was observed with respect to im-
munoreactivity or integrity. This and the fact that in 1983
Williams et al. [8] found remaining bioactivity even at
chloramine-T/BoNT-A molar ratios of 200 to 300 make
that damage from chemical oxidation cannot be the main
reason for the huge loss of bioactivity. Also, the most
effective chemoprotection against radiation damage
(no Cl− containing PBS but phosphate buffer [15],
addition of ascorbic acid and BSA [9]) before, during andEPES and/or lactose and iodination of BoNT-A










g IODOGEN in 17.5 μL IODOGEN/acetonitrile added at t = 0 and at t = 45. Other
s >98.5% in all experiments.
purposely added.
Figure 4 The results of the rat bladder strip in vitro model. Rat bladder strip mounted in two parallel organ baths and incubated in 125I-BoNT-A
(A) showing no inhibition of contraction force induced by electrical field stimulation (EFS) in time and unlabelled BoNT-A (B) showing inhibition of
contraction force induced by EFS in time. Both strips are simultaneously stimulated by potassium chloride (KCl; three times), carbachol (CCh; three
times), EFS (repetitive) and CCh (three times). The CCh-induced strip contraction before and after incubation is a viability check of the strip during
the experiment.
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implemented, ruling out radiation damage, if any, as pos-
sible reason.
Hence, we arrive at the conclusion that the main loss
of bioactivity does not originate from oxidative or radi-
ation damage but from the introduction of the iodine
atom itself, i.e. from the introduction of an apolar heavy
atom combined with the effect of the decrease of the
pKa of the iodinated phenol moiety from 10.0 to 8.9. A
strong extra argument in favour of this conclusion can
be derived from the fact that the averaged I/BoNT-A
molar ratio of our 125I-BoNT-A with specific activity of150.5 to 152.9 MBq/nmol is 1.86 to 1.90 (Table 3). This
means that within the Poisson distribution, around 15%
of the BoNT-A molecules do not bear an iodine atom, a
percentage that fairly correlates with the remaining bio-
activity in the ECL and Endopep assay. Also, the most
optimal findings of Williams et al. [8], obtained with a
chloramine-T/BoNT-A molar ratio of 23 to 35, fit with
this concept. Their 125I-BoNT-A products with a specific
activity of 700 to 712 and 1,532 to 1,750 Ci/mmol cor-
relate with an averaged I/BoNT-A molar ratio of 0.32
and 0.75, respectively, or within the Poisson distribution
with a zero iodination fraction of around 73% and 47%.
Figure 5 The results of the ECL and Endopep assay. The ECL signal of unlabelled BoNT-A, 125I-BoNT-A and reference BoNT-A (A). The Endopep
signal of unlabelled BoNT-A, 125I-BoNT-A and reference BoNT-A (B).
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remaining bioactivity of around 85% and 60%, respec-
tively, bearing in mind that in those days the starting
product contained a certain amount of contaminating
protein which was bio-inactive at forehand.
Labelling with 124I requires the addition of 200 pmol
iodine carrier to get efficient yields [16]. Our established
specific activity results with 125I-BoNT-A imply that this
carrier aspect will not lead to a labelling problem. 124I-
BoNT-A might therefore contribute to setting up a proto-
col for optimal dose injection and quantification in the
bladder wall in a selected panel of patients. It is very un-
certain, however, whether 124I-BoNT-A is representativefor the distribution of BoNT-A through the bladder wall
after intravesical injection. The heavy chain is important
for docking and endocytosis of BoNT-A in the nerve end
terminal, while the light chain cleaves SNAP-25 protein in
the nerve end terminal, SNAP-25 being essential in the fu-
sion of acetylcholine vesicles with the nerve end terminal
membrane [17]. When an iodine atom on essential tyro-
sine moieties blocks these subtle processes, it means that
the PET signal of the 124I-BoNT-A molecule does not re-
flect the behaviour of an unlabelled BoNT-A molecule at
cellular level.
On the basis of earlier studies with mAbs, we could
state (1) that one cannot unlimitedly change the positive
van Uhm et al. EJNMMI Research  (2015) 5:5 Page 9 of 9surrounding of lysine groups (for mice, the limit was
eight groups; for patients, four groups before seriously
affecting pharmacokinetics) [18], and (2) that the intro-
duction of a large hydrophobic group like IRDyeCW800
is limited to 1 [19]. The findings in this study allow us
to add a third statement, namely that the more specific
the macromolecule the less alterations, even small ones,
are permitted.
Conclusions
We have developed a mild reliable and efficient electro-
philic radio-iodination procedure for GMP-compliant
labelling of macromolecules on microgram scale. The in-
tegrity of a mAb molecule becomes impaired when on
average the number of introduced iodine atoms is ≥3.
For the very sensitive macromolecule BoNT-A, however,
a single introduced iodine atom already destroys the
bioactivity.
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